<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Mukherjee R</submitter><funding>Dutch Research Council (NWO)</funding><funding>Nederlandse Organisatie voor Wetenschappelijk Onderzoek (Dutch Research Council)</funding><pagination>14745</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9737664</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>23(23)</volume><pubmed_abstract>Human milk oligosaccharides (HMOs) and their most abundant component, 2'-Fucosyllactose (2'-FL), are known to be immunomodulatory. Previously, it was shown that HMOs and 2'-FL bind to the C-type lectin receptor DC-SIGN. Here we show, using a ligand-receptor competition assay, that a whole mixture of HMOs from pooled human milk (HMOS) and 2'-FL inhibit the binding of the carbohydrate-binding receptor DC-SIGN to its prototypical ligands, fucose and the oligosaccharide Lewis-B, (Le&lt;sup>b&lt;/sup>) in a dose-dependent way. Interestingly, such inhibition by HMOS and 2'-FL was not detected for another C-type lectin, langerin, which is evolutionarily similar to DC-SIGN. The cell-ligand competition assay using DC-SIGN expressing cells confirmed that 2'-FL inhibits the binding of DC-SIGN to Le&lt;sup>b&lt;/sup>. Molecular dynamic (MD) simulations show that 2'-FL exists in a preorganized bioactive conformation before binding to DC-SIGN and this conformation is retained after binding to DC-SIGN. Le&lt;sup>b&lt;/sup> has more flexible conformations and utilizes two binding modes, which operate one at a time via its two fucoses to bind to DC-SIGN. Our hypothesis is that 2'-FL may have a reduced entropic penalty due to its preorganized state, compared to Le&lt;sup>b&lt;/sup>, and it has a lower binding enthalpy, suggesting a better binding to DC-SIGN. Thus, due to the better binding to DC-SIGN, 2'-FL may replace Le&lt;sup>b&lt;/sup> from its binding pocket in DC-SIGN. The MD simulations also showed that 2'-FL does not bind to langerin. Our studies confirm 2'-FL as a specific ligand for DC-SIGN and suggest that 2'-FL can replace other DC-SIGN ligands from its binding pocket during the ligand-receptor interactions in possible immunomodulatory processes.</pubmed_abstract><journal>International journal of molecular sciences</journal><pubmed_title>Human Milk Oligosaccharide 2'-Fucosyllactose Inhibits Ligand Binding to C-Type Lectin DC-SIGN but Not to Langerin.</pubmed_title><pmcid>PMC9737664</pmcid><funding_grant_id>731.017.408</funding_grant_id><pubmed_authors>van Bergenhenegouwen J</pubmed_authors><pubmed_authors>Somovilla VJ</pubmed_authors><pubmed_authors>Chiodo F</pubmed_authors><pubmed_authors>van Kooyk Y</pubmed_authors><pubmed_authors>Kraneveld AD</pubmed_authors><pubmed_authors>Bruijns S</pubmed_authors><pubmed_authors>Mukherjee R</pubmed_authors><pubmed_authors>Pieters RJ</pubmed_authors><pubmed_authors>Garssen J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Human Milk Oligosaccharide 2'-Fucosyllactose Inhibits Ligand Binding to C-Type Lectin DC-SIGN but Not to Langerin.</name><description>Human milk oligosaccharides (HMOs) and their most abundant component, 2'-Fucosyllactose (2'-FL), are known to be immunomodulatory. Previously, it was shown that HMOs and 2'-FL bind to the C-type lectin receptor DC-SIGN. Here we show, using a ligand-receptor competition assay, that a whole mixture of HMOs from pooled human milk (HMOS) and 2'-FL inhibit the binding of the carbohydrate-binding receptor DC-SIGN to its prototypical ligands, fucose and the oligosaccharide Lewis-B, (Le&lt;sup>b&lt;/sup>) in a dose-dependent way. Interestingly, such inhibition by HMOS and 2'-FL was not detected for another C-type lectin, langerin, which is evolutionarily similar to DC-SIGN. The cell-ligand competition assay using DC-SIGN expressing cells confirmed that 2'-FL inhibits the binding of DC-SIGN to Le&lt;sup>b&lt;/sup>. Molecular dynamic (MD) simulations show that 2'-FL exists in a preorganized bioactive conformation before binding to DC-SIGN and this conformation is retained after binding to DC-SIGN. Le&lt;sup>b&lt;/sup> has more flexible conformations and utilizes two binding modes, which operate one at a time via its two fucoses to bind to DC-SIGN. Our hypothesis is that 2'-FL may have a reduced entropic penalty due to its preorganized state, compared to Le&lt;sup>b&lt;/sup>, and it has a lower binding enthalpy, suggesting a better binding to DC-SIGN. Thus, due to the better binding to DC-SIGN, 2'-FL may replace Le&lt;sup>b&lt;/sup> from its binding pocket in DC-SIGN. The MD simulations also showed that 2'-FL does not bind to langerin. Our studies confirm 2'-FL as a specific ligand for DC-SIGN and suggest that 2'-FL can replace other DC-SIGN ligands from its binding pocket during the ligand-receptor interactions in possible immunomodulatory processes.</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Nov</publication><modification>2026-04-08T11:33:33.146Z</modification><creation>2025-04-04T23:36:47.62Z</creation></dates><accession>S-EPMC9737664</accession><cross_references><pubmed>36499067</pubmed><doi>10.3390/ijms232314745</doi></cross_references></HashMap>